Evaluate the Effectiveness of Crosslinked HA on the Adhesion Preventing After Trigger Finger Rele… (NCT05082480) | Clinical Trial Compass
TerminatedNot Applicable
Evaluate the Effectiveness of Crosslinked HA on the Adhesion Preventing After Trigger Finger Release Surgery
Stopped: poor enrollment
Taiwan5 participantsStarted 2022-05-05
Plain-language summary
To Evaluate the Effectiveness of the use of a Novel Crosslinking Hyaluronan Hydrogel on the Prevention of the Adhesion Occurrence After Trigger Finger Release Surgery
Who can participate
Age range20 Years – 65 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Agree to participate in this study and sign informed consent form
✓. Age 20 to 65 years of male or female
✓. The trigger finger, except thumb, classified as 3 to 4 points and plan to conduct trigger finger release surgery;
✓. The trigger finger, except thumb, classified as 2 points with the symptom of flexion contracture and plan to conduct trigger finger release surgery;
✓. Agree to comply with the follow-up schedule of this study
Exclusion criteria
✕. Target finger has other adhesion in tendon, joint, or proximal nerve, neuropathy, compression injury or other disease;
✕. Other fingers in the same hand as the target finger have other adhesion in tendon, joint, or proximal nerve, neuropathy, or compression injury;
✕. Contralateral finger has other adhesion in tendon, joint, or proximal nerve, neuropathy, or compression injury;
✕. The operation site was conducted tendon transplantation or any surgery in past 6 months;
✕. Receiving orthopedic-related treatment which may affect the evaluation of the study;
✕. The skin of the operation site with infection, deficiency, or needing skin transplantation;
✕. With poorly controlled chronic diseases, such as diabetes mellitus;
What they're measuring
1
The percentage of Total Active Motion (TAM) score for target finger.
✕. Patient with autoimmune disease (such as rheumatoid arthritis), malignant tumors, coagulation diseases, heart diseases, mental diseases, etc., may cause patients to participate in the trial at higher risk;